In this free webinar, learn why antibody-drug conjugate (ADC) programs benefit from a "fail faster" approach to reduce late-stage attrition and accelerate development. Attendees will gain insight into ...

Antibody-drug conjugates (ADCs) are transforming oncology with their ability to deliver potent cytotoxic agents directly to tumor cells, combining the targeting precision of monoclonal antibodies with ...

Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...

On June 10, Alteogen, a bio-platform company, announced that it had released preclinical experimental results on the ...

(RTTNews) - WuXi XDC, a global leading Contract Research, Development and Manufacturing Organization dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated ...

MADISON, Wis, & NORTH BETHESDA, Md., October 22, 2025--(BUSINESS WIRE)--Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

WuXi XDC, a CRDMO, agreed to collaborate with Earendil Labs on WuXi XDC’s WuXiTecan-2 payload-linker technology platform. The partnership is aimed at accelerating the development of next-gen ADCs by ...

SAN DIEGO – October 14 th, 2015 — Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it is expanding its ...

The 5th ADC Analytical Development Summit is the only dedicated platform for tackling the unique analytical complexities of ADC development, bringing together technical leaders to ensure a ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...

TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in ...